Bleeding Clinical Trial
Official title:
Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients
Verified date | October 2023 |
Source | University of Virginia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the current pilot study proposal is to compare the use of the purified human fibrinogen concentrate (Fibryga®, Octapharma USA) to cryoprecipitate for the treatment of cardiopulmonary bypass (CPB)-associated bleeding in pediatric cardiac patients in whom fibrinogen supplementation is indicated. The investigators' hypothesis is that fibrinogen concentrate will be as effective as cryoprecipitate in achieving adequate hemostasis after separation from CPB in pediatric cardiac surgery patients. Study Design: this will be a single-center, prospective, randomized, active-control study in pediatric (24 months of age or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM). Informed consent will be obtained from a parent or a legal guardian prior to surgery and anesthesia. Once the need for fibrinogen supplementation is confirmed, study participants will be randomized into one of two treatment groups (n=15 in each group): 1. Cryoprecipitate group (dose: 10 ml/kg; active control group) or 2. Fibrinogen Concentrate group (dose: 70 mg/kg; intervention group). There will be no placebo group since withholding treatment is neither consistent with standard of care nor acceptable ethically. No other aspects of care will be modified. In the event that an additional dose of fibrinogen supplementation is required (bleeding with documented hypofibrinogenemia) cryoprecipitate will be administered to all study subjects (including those who received FC). The results of this study will be used for publication as well as the first stage towards a significantly larger randomized multi-center trial (see below). Based on the results of this pilot study the investigators plan to conduct a large multi-center, randomized active-control non-inferiority trial in the future, comparing the use of FC to cryoprecipitate in a much larger cohort of pediatric patients undergoing cardiac surgery with CPB. Ultimately, the results of this trial are likely to improve the care of pediatric cardiac surgical patients experiencing post-CPB bleeding, an under-studied yet high-risk patient population.
Status | Completed |
Enrollment | 30 |
Est. completion date | May 1, 2023 |
Est. primary completion date | March 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 24 Months |
Eligibility | Inclusion Criteria: - pediatric (age 24 months or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM). Exclusion Criteria: - gestational age < 33 weeks at birth - gestational age < 35 weeks on the day of surgery - emergency surgery - patient or parent history of coagulopathy/clotting abnormalities - patient history of thrombophilia - refusal to participate in the study, - known severe allergic reaction/anaphylaxis to fibrinogen concentrate, - administration of fibrinogen concentrate or cryoprecipitate in the 24 hours prior to surgery - baseline fibrinogen level higher than 300 mg/dL (to avoid the risk of increasing the fibrinogen level above the normal upper level of 400 mg/dL) |
Country | Name | City | State |
---|---|---|---|
United States | University of Virginia Health System | Charlottesville | Virginia |
Lead Sponsor | Collaborator |
---|---|
University of Virginia | Octapharma |
United States,
Fassl J, Lurati Buse G, Filipovic M, Reuthebuch O, Hampl K, Seeberger MD, Bolliger D. Perioperative administration of fibrinogen does not increase adverse cardiac and thromboembolic events after cardiac surgery. Br J Anaesth. 2015 Feb;114(2):225-34. doi: 10.1093/bja/aeu364. Epub 2014 Oct 16. — View Citation
Galas FR, de Almeida JP, Fukushima JT, Vincent JL, Osawa EA, Zeferino S, Camara L, Guimaraes VA, Jatene MB, Hajjar LA. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1647-55. doi: 10.1016/j.jtcvs.2014.04.029. Epub 2014 Apr 18. — View Citation
Haas T, Cushing MM, Asmis LM. Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro. Scand J Clin Lab Invest. 2018 May;78(3):230-235. doi: 10.1080/00365513.2018.1437645. Epub 2018 Feb 15. — View Citation
Haas T, Spielmann N, Restin T, Seifert B, Henze G, Obwegeser J, Min K, Jeszenszky D, Weiss M, Schmugge M. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: A prospective randomised controlled trial. Br J Anaesth. 2015 Aug;115(2):234-43. doi: 10.1093/bja/aev136. Epub 2015 May 15. — View Citation
Hvas AM, Andreasen JB, Christiansen K, Ravn HB. Ex-vivo response to blood products and haemostatic agents after paediatric cardiac surgery. Blood Coagul Fibrinolysis. 2013 Sep;24(6):587-92. doi: 10.1097/MBC.0b013e32836029d2. — View Citation
Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc. 2015 Jun 2;4(6):e002066. doi: 10.1161/JAHA.115.002066. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percent of patients requiring postoperative Extra Corporeal Membrane Oxygenation (ECMO) support | comparison between the groups of the incidence of the need for postoperative circulatory support with ECMO | from separation from CPB until postoperative day 30 (or discharge from the hospital (whichever occurs earlier) | |
Primary | A composite of the number of any allogeneic blood products (RBCs, plasma, platelets, cryoprecipitate) transfused from administration of the study medication until 48 hours after surgery | comparison between study groups of the number of allogeneic blood products transfused (RBC, plasma, platelets, cryoprecipitate) from immediately after the administration of the study drug (fibrinogen concentrate or cryoprecipitate) until 48 hours since admission to the ICU | from immediately after the administration of the fibrinogen concentrate or cryoprecipitate through the first 48 hours after admission to the ICU/post anesthesia care unit | |
Secondary | Comparison of post CPB bleeding (in ml) between the study groups | (intraoperatively = cell saver volume in ml; postoperatively = chest drain output in ml) | from administration of fibrinogen concentrate or cryoprecipitate until 48 hours after primary postoperative admission to the ICU | |
Secondary | Comparison of the number RBC units transfused immediately after administration of the study medication and until postoperative day 7 | Comparison between the study groups of the number of RBC units transfused immediately after administration of the study medication (fibrinogen concentrate or cryoprecipitate) until postoperative day 7 | From immediately after study medication administration through postoperative day 7 | |
Secondary | Comparison of the number platelets units transfused immediately after administration of the study medication and until postoperative day 7 | Comparison between the study groups of the number of platelets units transfused immediately after administration of the study medication (fibrinogen concentrate or cryoprecipitate) until postoperative day 7 | From immediately after study medication administration through postoperative day 7 | |
Secondary | Comparison of the number plasma units transfused immediately after administration of the study medication and until postoperative day 7 | Comparison between the study groups of the number of plasma units transfused immediately after administration of the study medication (fibrinogen concentrate or cryoprecipitate) until postoperative day 7 | From immediately after study medication administration through postoperative day 7 | |
Secondary | Comparison of additional number cryoprecipitate units transfused immediately after administration of the study medication and until postoperative day 7 | Comparison between the study groups of the number of additional cryoprecipitate units transfused immediately after administration of the study medication (fibrinogen concentrate or cryoprecipitate) until postoperative day 7 | From immediately after study medication administration through postoperative day 7 | |
Secondary | Incidence of postoperative surgical chest re-exploration for excessive bleeding/cardiac tamponade | Comparison between study groups of the incidence of postoperative surgical chest re-exploration in the ICU/OR for excessive bleeding or cardiac tamponade | from admission to the ICU until postoperative day 7 | |
Secondary | Incidence of the use of Factor VIIa for bleeding | comparison of percent of patients requiring factor VIIa for bleeding (intraoperatively or postoperatively in the ICU between the study groups | from separation from CPB until 48 hours after surgery | |
Secondary | In-hospital mortality | comparison of the incidence of in-hospital mortality between the study groups | from admission to the ICU until 30 days after the operation/discharge from the hospital (whichever is earlier) | |
Secondary | Post operative Acute Kidney injury (AKI) | comparison of the incidence of postoperative AKI between study groups. AKI will be assessed based on the Acute Kidney Injury Network (AKIN) classification (stages 0-3, with higher stage reflecting worse outcome) | from admission to the ICU until postoperative day 7 | |
Secondary | Postoperative infection | comparison of the incidence of pneumonia, sternal wound infection, mediastinitis, sepsis between study groups | rom admission to the ICU until 30 days after the operation/discharge from the hospital (whichever is earlier) | |
Secondary | percent of patients with postoperative neurological injury | Comparison between study groups of the percent of patients with seizures/stroke that occur after surgery | from admission to the ICU until POD 7 | |
Secondary | Intubation time | comparison of the time to extubation from the completion of surgery until extubation in the ICU between the study groups | from admission to the ICU until 30 days after surgery or discharge from the ICU (whichever is earlier) | |
Secondary | postoperative thromboembolic event | comparison of the incidence of DVT/PE/shunt thrombosis between the study groups | from admission to the ICU until 7 days postoperatively | |
Secondary | ICU length of stay | comparison of the postoperative time period spent in the ICU | from admission to the ICU after surgery until 90 days after surgery or discharge from the ICU (whichever occurs earlier) | |
Secondary | Hospital length of stay | comparison between the study groups of the time in the hospital from admission to the ICU postoperatively until discharge from the hospital | from admission to the ICU postoperatively until postoperative day 90 or discharge from the hospital (whichever occurs earlier) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04058223 -
Comparison of the Short-term Outcomes of Using DST and PPH Staplers in the Treatment of Grade III and IV Hemorrhoids
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT05669313 -
The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
|
||
Completed |
NCT04590898 -
Peri-device Leakage Closure After LAAO
|
||
Active, not recruiting |
NCT05563883 -
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
|
||
Not yet recruiting |
NCT04537533 -
Tranexamic Acid Infusion in Low Dose Versus in High Dose for Reducing Blood Loss in Radical Cystectomy Operations
|
Phase 4 | |
Withdrawn |
NCT02851940 -
Pain and Bleeding Following Hypertonic Saline Sclerotherapy Compared to Brand Ligation for Symptomatic Hemorrhoids
|
N/A | |
Completed |
NCT02722720 -
Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral
|
N/A | |
Recruiting |
NCT02279186 -
Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section
|
Phase 4 | |
Active, not recruiting |
NCT02244853 -
Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease
|
N/A | |
Completed |
NCT02245854 -
Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Small Colorectal Polyps
|
N/A | |
Completed |
NCT02980497 -
Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study
|
N/A | |
Completed |
NCT02092415 -
Assessment of Limb Perfusion During Junctional Tourniquet
|
N/A | |
Not yet recruiting |
NCT01438736 -
Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?
|
Phase 4 | |
Completed |
NCT00515541 -
Lovaza's Effect on the Activation of Platelets
|
Phase 2 | |
Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
Terminated |
NCT03954314 -
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
|
Phase 3 | |
Recruiting |
NCT05945680 -
Tranexamic Acid in Breast Esthetic Surgery.
|
Phase 4 | |
Recruiting |
NCT03783182 -
Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy
|
Phase 4 | |
Not yet recruiting |
NCT05464394 -
Peroperative Administration of Tranexamic Acid in Roux-en-Y Gastric Bypass and One-anastomosis Gastric Bypass
|
Phase 3 |